Results 81 to 90 of about 882 (153)

Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance

Interdisciplinary Perspectives on Infectious Diseases, Volume 2026, Issue 1, 2026.
Meropenem is a broad‐spectrum carbapenem antibiotic essential for treating serious infections including urinary tract infections, pneumonia, sepsis, and meningitis. This narrative review examines meropenem resistance trends and prescribing practices for severe infections in Pakistan highlighting how inappropriate use drives local antimicrobial ...
Nasim Akhtar, Ejaz Ahmed Khan, Summiya Nizamuddin, Sana Anwar, S. H. Waqar, Sarwat Faisal, Sarmad Iqbal, Divakar Sharma   +7 more
wiley   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

Infection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R   +3 more
doaj  

Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES‐1 by enmetazobactam and tazobactam

FEBS Letters, Volume 599, Issue 22, Page 3284-3300, November 2025.
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R. Bethel, Catherine L. Tooke, Marc W. Van der Kamp, Krisztina M. Papp‐Wallace, Robert A. Bonomo, Stuart Shapiro, Adrian J. Mulholland, James Spencer   +10 more
wiley   +1 more source

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis

, 2018
The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant ...
Kelly Peterson, Phung Nguyen, William J. Weiss, David Valtierra, David C. Griffith, Jerry W. Simecka, Mark E. Pulse, Mojgan Sabet, Jessica Silva   +8 more
core   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

Vaborbactam: perspective of a new β-lactamase inhibitor in the antimicrobial chemotherapy

, 2023
<p>Infections due to carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii constitute a global public health threat and are associated with high morbidity and mortality rates.
Koumaki, V., Amargianitaki, E., Papaparaskevas, J., Tsakris, A.   +3 more
core   +1 more source

Ex vivo characterisation of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam

, 2018
The combination product meropenem/vaborbactam, with activity against KPC-producing carbapenem resistant Enterobacteriaceae, is likely to be used during renal replacement therapy. The aim of this work was to describe the extracorporeal removal (adsorption
Sime, Fekade B., Lipman, Jeffrey, Alexander, Elizabeth, Karamujic, Nermin, Durso, Stephanie, Griffith, David, Pandey, Saurabh, Wallis, Steven C., Parker, Suzanne, Loutit, Jeffery, Roberts, Jason A.   +10 more
core   +1 more source

Comparisons of vaborbactam-bound PBP3 with the P. aeruginosa PBP3-β-lactam, monobactam, and DBO complexes.

, 2021
A, vaborbactam-bound PBP3 structure with ligand in ball-and-stick representation with cyan-colored carbon atoms. The ligand’s oxygen located in the oxyanion hole (a), the carboxyl (b), the amide (c), and the five-membered thiophene (d) are labeled.
Vijay Kumar (377076), Jeeda Ismail (11570566), Focco van den Akker (158508), Shreya Agarwal (774270), Samantha L. Viviani (11570563), Robert A. Bonomo (188763)   +5 more
core   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae

Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4
Thomas Lavoie, Teresa Sierra, Katie Daffinee, Jason M. Pogue, Brahim Achour, Kerry LaPlante   +5 more
doaj   +1 more source